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Summary.-Previous studies suggested that aprotinin might enhance the host's
immunological resistance to tumours. This possibility has now been further
investigated by studying the behaviour of tumours in both hamsters and mice.
A second tumour graft in tumour-bearing hamsters appeared more rapidly than
the first. Prior administration of aprotinin abolished this effect. Pretreatment
of non-cancerous mice with cortisone nullified the effectiveness of aprotinin in
inhibiting the growth of a subsequent tumour graft. These results are interpreted
as additional evidence that aprotinin enhances the immunological system against
tumour cells.
IT HAS previously been shown that
the anti-proteinase, aprotinin, has con-
siderable inhibitory properties against
the growth and spread of tumour cells
in animals (Latner, Longstaff and Turner,
1974). Histological examination of the
tumour from the aprotinin-treated animals
indicated that tumour necrosis was ac-
companied by marked round-cell infiltra-
tion. This suggested to us that the
proteolytic enzymes of malignant cells
might be playing a part in relation to
the inhibition of immunological attack
by the host, and that the administration
of aprotinin might prevent this process.
It was decided, therefore, to test the
effect of aprotinin on immunological
resistance to tumour cell growth using a
fibrosarcoma in hamsters and an adeno-
carcinoma in mice. In the latter case,
cortisone was administered prior to tumour
implantation and subsequent aprotinin
treatment.
MATERIALS AND METHODS
Animals.-3-4-month-old inbred male Sy-
rian hamsters and inbred female C3H mice
(Heston specific) were used. The hamsters
were raised in our laboratories and the
mice were obtained commercially (Bantin
and Kingman Limited, Aldbrough, North
Humberside).
Tumour cells.-The cells used to raise
tumours in the hamsters and the mice have
been described previously (Latner et al.,
1974). These will be subsequently referred
to as TRES and SMA cells respectively.
The TRES cells were grown in tissue culture
prior to implantation but the SMA cells
were propagated by serial transplantation
(loc. cit.). After implantation of tumour
cells, the animals were examined daily for
tumour growth, in a blind fashion, and the
day on which it first became just palpable
was recorded as the day of appearance.
There was, of course, subsequent increase
in size. Growing tumours were obtained in
all animals challenged.
Substances used for treatment. Saline was
administered as a 0.9% (w/v) solution of
sodium chloride in sterile water. Aprotinin
(Trasylol, Bayer Pharmaceuticals, Haywards
Heath, Sussex) was administered as supplied
by the manufacturers, who claim an activity
of 10,000 kallikrein-inactivating units/ml.
Cortisone acetate (The Boots Company
Limited, Nottingham) was administered as
a suspension, the commercially available
material being diluted to 4 mg/ml with the
sterile saline solution. Injections were given
to the hamsters by the intraperitonealA. L. LATNER AND G. A. TURNER
route and to the mice subcutaneously
(s.c.).
Hamiister observations.-05 x 1O6 TRES
cells in 0 5 ml medium 199 (Flow Laboratories
Limited, Irvine, Ayrshire) were implanted s.e.
into the left dorso-lumbar region of each
hamster. Eighteen days after implantation
the animals were divided randomly into
twro groups. One group was treated with
1 ml saline twice daily for 14 days, and the
other with 1 ml aprotinin twice daily for
the same length oftime. After the treatment
hald ended all animals were given another s.e.
implant of 0-5 x 106 TRES cells; this time
into the right scapula region. The times
of first appearance of palpable tumours
from the first and second grafts were noted.
Mouse observations.-Two groups of mice
(Group A and Group B) were treated with
either 0-1 ml saline or 0-1 ml cortisone
acetate respectively for 28 days. After treat-
ment, 0.5 ml SMA tumour (Latner et al.,
1974) w%Aas implanted into the dorso-lumbar
region of each mouse. The two groups
were further subdivided into groups Al, A2
and BI, B2. Three days post-implantation,
Group Al and Group Bi received 0 5 ml
saline twice daily for 7 days, and Group A2
and Group B2 received 0 5 ml aprotinin
twice daily for the same period. The mice
were then left for one day, sacrificed, and
each tumour dissected out to determine its
wNet weight.
RESULTS
D)ifferences between groups were ana-
lysed statistically using the Mann Whitney
U-test. The results obtained in the
hamster groups are shown in the Figure.
In the animals subsequently given saline
and in those subsequently given aprotinin,
the appearance of the first tumour graft
was not significantly different (P > 0.5).
Hence, these two sets of data are pooled
in the Figure, and referred to as " first
graft ". After saline administration the
second tumotur graft appeared signifi-
cantly earlier then the first graft
(P- 0005). This did not happen with
the aprotinin treated animals (P > 0.05),
and the second tumour graft took signifi-
cantly longer to develop in the aprotinin
group than in those receiving saline
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Fi,.-Relationship bet-ween percentage of
hamsters with palpable tutmouir and time
after implantation; * 0 (31
animals) first tumour graft; A -A
(15 animals) secondl tumour graft, saline-
pretreated; *------ * (16 animals) secon(d
tumour graft, aprotinin-pretreatedl.
TABLE. Effect of Aprotinin on Growth
of an Adenocarcinomna in Mice Pre-
treated with Cortisone
Weight of tumour (g)
obtained from each mouse
in the different treatment
groups I1 dlays after
implantation
Al A2 BI B2
Cortisone
Aprotinin
P value ulsinig Manil
Whitney U-test
_ +
1-8 O1I
3-(0 0 7
3 (0 1-0
4-2 10
4 3 1-1
5.1 1-2
65- 3-9
6-8
<0 0001
1-0 1-7
2-8 3 (0
2-9 3-8
3-9 3-9
3-4 40
4-4 4-7
a-2 4-9
5-6
>0-05
See text for treatment (letails.
alone (P < 0-001). Seventy-five per cent
of hamsters in each group were chosen
randomly and autopsied. Macroscopic
metastases, mainly in the liver, lungs,
kidneys, body wall and lymph glands,
were found in 40%0 and 80% of the
aprotinin- and saline-treated groups re-
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spectively. Tissues have not yet been
examined extensively for microscopic
metastases.
The results obtained in the mouse
groups are shown in the Table. Treat-
ment of animals with aprotinin (A2)
significantly inhibited tumour growth in
animals pretreated with saline compared
to the appropriate control group (Al)
(P < 0 001). However, pretreatment of
the animals with cortisone abolished the
effectiveness of the aprotinin treatment
(P > 0 05). Since there was no signifi-
cant difference between groups Al, B1I
and B2, a second experiment was per-
formed using three groups, which cor-
responded to groups A2 (6 animals), Bi
(8 animals) and B2 (8 animals). Here
again there was no significant difference
between tumour weights in groups B1
and B2, but tumour weights in group
A2 were once again significantly lower
than in the other two (P < 0.01).
DISCUSSION
We believe that the results presented
in this communication provide further
evidence that aprotinin is enhancing the
effectiveness of the immunological system
in dealing with tumour cells. The reasons
for this belief are two-fold. The first
is that more rapid take of a second
tumour graft in tumour-bearing animals
can be interpreted as immune paralysis
(Stjernsward, 1966) by the already present
substantial growth. Thus abolition of
this effect by aprotinin treatment suggests
that the anti-proteinase is preventing
such immune paralysis. Since the effect
was observed only when the host had
already been challenged with tumour
cells, it would appear that the aprotinin
was interfering directly with the immuno-
logical attack by the sensitized host
rather than non-specifically stimulating
the immunological system prior to re-
ceiving the tumour implant.
A second reason for the belief that
the immunological response has been
enhanced by aprotinin is concerned with
the results obtained after cortisone treat-
ment, which is known to brinig about
immunosuppression. Although the mode
of action of adrenal corticosteroids at
the cellular level is poorly understood,
recent in vitro studies have shown that
corticosteroids suppress the effect of
lymphotoxins (Williams and Granger,
1969), monocyte chemotactic factor (Riihl
et al., 1974), macrophage aggregation
factor (Gaumer et al., 1974), and macro-
phage migration inhibitory factor (Balow
and Rosenthal, 1973). We have found
(unpublished observations) that treat-
ment of C3H/He mice with cortisone
increased the median survival time of
tail-skin homografts from 15 days to
18 days (P < 0 005); the proportion of
animals having viable grafts at 20 days
in the untreated (41 animals) and treated
(37 animals) groups being 10% and
41% respectively. It can therefore be
assumed that aprotinin was unable to
affect tumour growth in cortisone-pre-
treated mice because of depletion of the
immune response to the implanted cells.
It is interesting to note that pretreatment
ofanimals with cortisone did not stimulate
tumour growth in the non-aprotinin-
treated mice as compared with their
respective saline controls. This observa-
tion serves to illustrate the fact that
though the host may have detected the
presence of tumour cells, it was unable
to mount any effective attack againist
them, possibly because of the extreme
malignancy of the adenocarcinoma being
implanted.
We have not yet obtained direct
evidence for immunogenicity for either
of the tumour lines in the autologous
situation. We have, however, in pre-
liminary experiments, succeeded in pro-
ducing an antiserum in the rabbit which
after absorption by adult hamster tissues
gave a positive result against TRES
cells by indirect immuinofluorescence.
These observations are being followecl
up, including extension to the SMA
cells as well as to the autologous situation.
We have previously suggested (Latner
et al., 1974) that aprotinin may operate
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by inhibiting proteolytic digestion of
tumour-specific antibodies attached to
the T-lymphocyte. It could possibly be
argued that aprotinin disappears from
the circulation too rapidly (Vogel, Traut-
scheld and Werle, 1968) for this to occur.
It has now, however, been recognized
that aprotinin binds specifically to sialosyl
and uronosyl groups in carbohydrate-
containing substances (Stoddart and Kier-
nan, 1973). Consequently, injected apro-
tinin should bind to mucosubstances on
the surfaces of sensitized lymphocytes and
even tumour cells, and so maintain the
level of the anti-proteinase in the imme-
diate region of these cells. This would
not affect the half-life of aprotinin as
measured in plasma (Vogel et al., 1968).
The adherence of aprotinin to cell surfaces
would account for the effect on the
appearance of a second tumour graft
even though the substance had ceased to
be administered.
We are indebted to Bayer Pharma-
ceuticals Limited for their generous supply
of aprotinin used throughout these in-
vestigations.
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